Anjarium Biosciences AG


Product Categories: Exosome-based therapeutics


Anjarium at the forefront of the emerging field of exosome-based therapeutics, with a focus on advancing its pipeline of targeted nucleic acid medicines for cancer and rare monogenic diseases. Anjariums’ platform creates unmatched advantages in the realm of engineering exosome-based drugs to harnessing the naturally occurring communication between cells for RNAi, mRNA and gene editing-based therapeutics. Exosome-based drugs may address some of the limitations of nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other delivery modalities, and Anjarium is a leader in this emerging therapeutic space.


Contact: Joel de Beer, info@anjarium.com

Industry Sectors

  • Biotech

Participated Fairs

Anjarium Biosciences AG

Wagistrasse 25
8952 Schlieren


Recommend us

Premium Partner

Strategic partners

Institutional partner

Official program